Home > Haematology > EHA 2021 > Leukaemia > GLOW: Ibrutinib + venetoclax showed superior PFS as first-line CLL treatment

GLOW: Ibrutinib + venetoclax showed superior PFS as first-line CLL treatment

Presented By
Prof. Arnon Kater, Amsterdam University Medical Centres, the Netherlands
Conference
EHA 2021
Trial
Phase 2, GLOW
Fixed-duration ibrutinib + venetoclax showed superior efficacy in older or unfit patients with chronic lymphocytic leukaemia (CLL) compared with chlorambucil + obinutuzumab in the phase 3 GLOW study. These results support the positive clinical profile of all-oral, once-daily, fixed-duration ibrutinib + venetoclax as first-line treatment. Prof. Arnon Kater (Amsterdam University Medical Centres, the Netherlands) presented the primary results of the randomised, open-label, phase 3 GLOW study (NCT03462719) [1]. The once-daily, all-oral, fixed-duration therapy induced deep remissions in young or fit patients in the phase 2 CAPTIVATE study (NCT02910583), with 2-year progression-free survival (PFS) of 95% [2]. A total of 211 patients ≥65 years of age or <65 years with c...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on